
    
      Patients with relapsed small cell lung cancer (SCLC), head and neck carcinoma (H&N),
      neuroendocrine tumors (NETs), biliary tract carcinoma, endometrial carcinoma, BRCA
      1/2-associated metastatic breast carcinoma, carcinoma of unknown primary site, germ cell
      tumors (GCTs), and Ewing's family of tumors (EFTs) will be enrolled in nine different
      cohorts. Up to 25 evaluable patients are planned to be enrolled in each cohort (50 in the
      endometrial carcinoma and 100 in the SCLC cohort).
    
  